Histology

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Cancer, Nature Communications, Research and development, DLT, MSS, Safety, Pharmacokinetics, Colorectal cancer, CRC, Tumor microenvironment, VISTA, Sensei, IND, Administration, Part-time, ASCO, Keystone, Therapy, Patient, Society, Histology, Neoplasm, Biology, VSIG4, CD39, Annual general meeting, NSCLC, Lung cancer, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Key Points: 
  • BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.
  • In January 2024, Sensei announced a realignment of its resources to fully support the Phase 1/2 clinical trial of SNS-101.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.8 million for the quarter ended March 31, 2024, compared to $5.8 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $8.0 million for the quarter ended March 31, 2024, compared to $10.2 million for the quarter ended March 31, 2023.

Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc.

Retrieved on: 
日曜日, 5月 5, 2024
Sale, FDA, Lead, Cirrhosis, Fatty liver disease, LLP, EFX, News, NASH, 8-K, District court, HERE, Patient, Non-alcoholic fatty liver disease, Histology, Fibrosis, Drug development, Therapy, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

DigitCells Unveils Proprietary TWO-D system at AUA 2024, Revolutionizing Pathology Workflows

Retrieved on: 
水曜日, 5月 1, 2024
Prostate, American Urological Association, Breast, LIS, Pathology, Intelligence, Digital, Environment, GI, Marie Cassidy, Histology, Acquisition, IMS, AUA, Annual general meeting, Medical director, Dermatology, Overalls, Medical imaging

CHICAGO, May 1, 2024 /PRNewswire-PRWeb/ -- DigitCells, a leading innovator in complete digital pathology solutions and a subsidiary company of GoPath Diagnostics, is excited to announce the launch of its groundbreaking Tissue Workflow Optimization for Digital (TWOD) system for prostate at the upcoming 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The TWOD system represents a revolutionary leap in pathology workflows, delivering unprecedented efficiency gains and setting a new benchmark in digital pathology."
  • Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics
    The TWOD system streamlines biopsy tissue workflows, significantly enhancing efficiency to meet the demands of today's pathology environment.
  • This process is centrally managed by TWOD's LIS and IMS system which integrates laboratory information and pathology imaging with embedded augmented intelligence and pathology sign-out functions.
  • The TWOD system bridges the gap between histopathology and digital pathology, reducing cost and improving workflow efficiency.

Veranex Acquires Leading Pathology and Histology Provider HORUS Scientific

Retrieved on: 
水曜日, 5月 1, 2024
Pathology, Growth, Engineering, DVM, GLP, Acquisition, Histology, Good laboratory practice, Knowledge

RALEIGH, N.C., May 1, 2024 /PRNewswire/ -- Veranex, the first purpose-built, integrated global service platform for the medtech industry, announced that it has acquired HORUS Scientific, a pathology and histology facility. This acquisition further solidifies Veranex's global commitment by deepening its end-to-end service capabilities for medtech innovation.

Key Points: 
  • "The growth of Veranex is a direct result of unwavering commitment to our clients' success," said Pat Donnelly, Chairman and CEO of Veranex.
  • "By joining forces with HORUS Scientific, we are not only expanding our footprint but enriching our collective expertise, strengthening our histology service capabilities, and enhancing the value we bring to our clients and partners."
  • "HORUS is excited to join the Veranex team — an organization with an outstanding reputation," said Dr. Stanley.
  • The additional capability added in North America will complement Paris's globally integrated in-house pathology and histology services, strengthening Veranex's overall pathology service line.

DigitCells Unveils Proprietary TWO-D system at AUA 2024, Revolutionizing Pathology Workflows

Retrieved on: 
火曜日, 4月 30, 2024
Prostate, American Urological Association, Breast, LIS, Pathology, Intelligence, Digital, Environment, GI, Marie Cassidy, Histology, Acquisition, IMS, AUA, Annual general meeting, Medical director, Dermatology, Overalls, Medical imaging

CHICAGO, April 30, 2024 /PRNewswire-PRWeb/ -- DigitCells, a leading innovator in complete digital pathology solutions and a subsidiary company of GoPath Diagnostics, is excited to announce the launch of its groundbreaking Tissue Workflow Optimization for Digital (TWOD) system for prostate at the upcoming 2024 American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The TWOD system represents a revolutionary leap in pathology workflows, delivering unprecedented efficiency gains and setting a new benchmark in digital pathology."
  • Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics
    The TWOD system streamlines biopsy tissue workflows, significantly enhancing efficiency to meet the demands of today's pathology environment.
  • This process is centrally managed by TWOD's LIS and IMS system which integrates laboratory information and pathology imaging with embedded augmented intelligence and pathology sign-out functions.
  • The TWOD system bridges the gap between histopathology and digital pathology, reducing cost and improving workflow efficiency.

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on: 
月曜日, 4月 22, 2024
TRACER, Histology, Mouse, Phenotype, Data science, Cell, AAV, CNS, Machine learning, Senior, Tauopathy, Gene, Process, Society, BBB, ALS, Central nervous system, Public, HEK293, Therapy, Centrifuge, SOD1, Vaccine

“Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.

Key Points: 
  • “Voyager’s novel TRACER-derived capsids underlie 13 partnered programs and three wholly-owned programs to enable IV-delivery of gene therapies for diseases of the central nervous system.
  • Three of those programs now have development candidates selected, and we see the potential for them to enter clinical trials next year,” said Todd Carter, Ph.D., Chief Scientific Officer of Voyager Therapeutics.
  • ET
    Intravenous administration of BBB-penetrant, MAPT-Silencing, AAV gene therapy provides broad and robust CNS Tau lowering in tauopathy mouse models (#1602).
  • ET
    Intravenous delivery of AAV gene therapy for the treatment of SOD1-ALS provides broad SOD1 lowering in NHP (#1647).

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Retrieved on: 
水曜日, 5月 1, 2024
Health, Technology, Health Technology, Artificial Intelligence, Oncology, Jane, Risk, American Urological Association, Recurrence, BCG, Docetaxel, CHAI, Data, University, Patient, Histology, Physician, AUA, Multimedia, Toxicity, Biomarker, Neoplasm, Associate, Medicine, Bladder cancer, Labs, Medical imaging

The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.

Key Points: 
  • The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240501832149/en/
    The CHAI biomarkers offer independent prognostic capabilities for high-grade recurrence and muscle-invasive progression in bladder cancer.
  • Validated across more than 1,000 patients and 12 centers, these biomarkers, available through the Vesta test, can enhance first-line treatment decision-making for non-muscle invasive bladder cancer.
  • We are able to visualize these biomarkers and gain a better understanding of how tumor morphology correlates to treatment response.”

NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.

Retrieved on: 
水曜日, 5月 1, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, FDA, Lead, Cirrhosis, Fatty liver disease, LLP, EFX, News, NASH, 8-K, District court, HERE, Patient, Non-alcoholic fatty liver disease, Histology, Fibrosis, Drug development, Therapy, Pharmaceutical industry

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) ( NASDAQ: AKRO ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) ( NASDAQ: AKRO ).
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

Clarapath Forms Strategic Collaboration with Mayo Clinic to Advance Pathology Tissue Processing

Retrieved on: 
火曜日, 4月 23, 2024
Technology, Other Health, Health, Oncology, Robotics, Health Technology, Medical Devices, Software, Artificial Intelligence, Hardware, Electronic Design Automation, Education, Mayo Clinic, Laboratory, Safety, Anatomical pathology, Medical laboratory, Research, Pathology, Intelligence, Automation, Patient, Histology, Organization, Medical imaging

Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.

Key Points: 
  • Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.
  • The strategic collaboration combines Clarapath’s innovative tissue solution and domain experts with the clinical insights and expertise of Mayo Clinic.
  • “We are thrilled to collaborate with Mayo Clinic to advance the modernization of anatomic pathology,” said Eric Feinstein, CEO of Clarapath.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.